Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas - Sorafenib in NF2 Investigation of the intra-tumoural concentration and activity of sorafenibin cutaneous schwannomas ...
Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas - Sorafenib in NF2 Investigation of the intra-tumoural concentration and activity of sorafenibin cutaneous schwannomas ...
Neurofibromatosis, type 2 (acoustic neurofibromatosis) MedDRA version: 14.0;Level: LLT;Classification code 10029271;Term: Neurofibromatosis, type 2 (acoustic neurofibromatosis);System Organ Class: 10010331 - Congenital, familial and genetic disorders Neurofibromatosis, type 2 (acoustic neurofibromatosis) MedDRA version: 14.0;Level: LLT;Classificatio ...
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Sorafenibto Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform N ...
Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar) in Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib(BAY 43-9006, Nexava ...